Dapagliflozin Safety and Efficacy at eGFR 41

Key Safety Considerations

The American College of Cardiology recommends dapagliflozin can be safely initiated when eGFR ≥25 mL/min/1.73 m² for cardiovascular and renal protection, making an eGFR of 41 well within the safe range 1
At eGFR 41, prescribe dapagliflozin 10 mg once daily for cardiovascular/renal protection, not for diabetes control, as the glucose-lowering efficacy is significantly reduced due to its mechanism of action 1

Dapagliflozin reduced the primary composite outcome (≥50% sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death) by 39% (HR 0.61 [95% CI 0.51-0.72]) in patients with eGFR 25-75 mL/min/1.73 m², according to the DAPA-CKD trial 1
The renal-specific composite outcome was reduced by 44% (HR 0.56 [95% CI 0.45-0.68]) 1
Cardiovascular death or heart failure hospitalization was reduced by 29% (HR 0.71 [95% CI 0.55-0.92]) 1

Anticipate a transient, reversible eGFR decrease of 3-5 mL/min/1.73 m² within the first 1-4 weeks, which represents hemodynamic adjustment rather than kidney injury 1, 2
Check eGFR and creatinine within 1-2 weeks after initiation to document this expected change 1

Assess volume status before starting dapagliflozin and correct any volume depletion, and consider reducing concurrent loop or thiazide diuretic doses to prevent excessive volume depletion, especially in elderly patients or those already on diuretics, as recommended by the Journal of the American College of Cardiology 1, 3
Monitor for orthostatic lightheadedness or signs of volume depletion, particularly in the first few weeks 3
If the patient is on insulin or sulfonylureas, reduce sulfonylurea dose by 50% or discontinue if already on minimal dose, and/or reduce total daily insulin dose by 20% to manage hypoglycemia risk, as recommended by the Journal of the American College of Cardiology 3

Instruct the patient to stop dapagliflozin immediately during any acute illness, particularly with reduced food or fluid intake, fever, vomiting, or diarrhea, and monitor for euglycemic diabetic ketoacidosis (DKA) 1
Withhold dapagliflozin at least 3 days before major surgery or procedures requiring prolonged fasting to prevent postoperative ketoacidosis 1

Genital mycotic infections occur in approximately 6% of patients, and urinary tract infections are more common with SGLT2 inhibitors, so counsel about daily hygienic measures and monitor for these adverse effects 1
Rare but serious adverse effects include necrotizing fasciitis of the perineum (Fournier gangrene), which requires prompt treatment if suspected 1